Hong Kong's innovative drug sector witnessed a collective surge, with Sino Biopharmaceutical leading the pack with a jump of over 28%. Other notable companies, including Chi-Med, Everest Medicines, 3SBio, and Lepu Medical Technology, also registered substantial gains. This upswing was fueled by policy support from relevant authorities aimed at fostering high-quality development in the innovative drug industry and facilitating the utilization of medical insurance data in research and development. Industry experts emphasized that the growth of commercial insurance will emerge as a significant catalyst for the advancement of the innovative drug sector. The year 2025 is seen as a pivotal point for the valuation enhancement of China's innovative drugs, with favorable policies anticipated to draw in more long-term investments into this domain. These initiatives have not only enhanced the research and development landscape for innovative drugs but also bolstered market confidence and elevated the valuation of innovative drug enterprises.